Allogene Therapeutics Inc
ALLO
查看详细走势图
2.260USD
-0.150-6.22%
收盘 03/27, 16:00（美东）报价延迟15分钟
260.41M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-6.22%
5天
+9.18%
1月
-18.71%
6月
+77.95%
今年开始到现在
+64.96%
1年
+45.81%
查看详细走势图
TradingKey Allogene Therapeutics Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
Allogene Therapeutics Inc当前公司基本面数据相对谨慎，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名108/391位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价7.42。中期看，股价处于上升通道。近一个月，市场表现较差，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Allogene Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Allogene Therapeutics Inc亮点
亮点风险
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
估值低估
公司最新PE估值-2.61，处于3年历史低位
机构加仓
最新机构持股141.70M股，环比增加0.07%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值514.44K
活跃度增加
近期活跃度增加，过去20天平均换手率0.37
分析师目标
根据
15
位分析师
买入
评级
7.418
目标均价
+207.81%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Allogene Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Allogene Therapeutics Inc简介
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
公司代码ALLO
公司Allogene Therapeutics Inc
CEOChang (David D)
网址https://allogene.com/
相关品种
